

PACE

PROVIDER BULLETIN

June 7, 2017

DUR EDITS

Beginning Monday, July 10, 2017, PACE will begin reviewing and placing restrictions on opioids and high risk medications.

OPIOIDS AND BENZODIAZEPINES/SEDATIVE HYPNOTICS USED IN COMBINATION

Prescriber(s) will be notified. Response will dictate the application of a Medical Exception for continued use or if one or more of the medications used in the combination is denied with NCPDP Error 70, "Drug Not Covered".

OPIOIDS, BENZODIAZEPINES/SEDATIVE HYPNOTICS AND MUSCLE RELAXANTS USED IN COMBINATION

Prescriber(s) will be informed that the muscle relaxant will be denied after 90 days with NCPDP Error 70, "Drug Not Covered". Edit will initially apply to cardholders beginning this therapy. (*Note: Current cardholders with this combination appearing consistently in history will be "grandfathered".*)

SEDATIVE HYPNOTICS

FDA indication is for short term use. A maximum duration edit will permit payment for 90 days of therapy throughout the year. Claims exceeding 90 days will deny for NCPDP Error 76, "Plan Limitations Exceeded". Edit will initially apply to cardholders beginning this therapy. (*Note: Current cardholders whose history shows consistent use will be "grandfathered".*)

BENZODIAZEPINES

A maximum duration edit will permit payment for 90 days. At the end of 90 days, the prescriber will be notified. If a medical exception is not warranted, claims will deny for NCPDP Error 76, "Plan Limitations Exceeded".

STIMULANTS AND SEDATIVE HYPNOTICS USED IN COMBINATION

If overlapping days' supply occurs within the past 90 days, claims will deny with NCPDP Error 70, "Drug Not Covered".

OPIOID AND BUPRENORPHINE PRODUCTS

When an opioid claim is submitted, history will be reviewed. If recent history reveals a buprenorphine product resulting in a day's supply overlap, the claim will deny for NCPDP Error 88, "Drug to Drug" interaction.

Questions may be directed to Provider Services at 1-800-835-4080.